The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -74,620 |
| Depreciation and amortization | 7,172 |
| Amortization of premiums and discounts on marketable securities | 1,648 |
| Share-based compensation | 14,286 |
| Gain on royalty monetization arrangement | 0 |
| Gain on sale of margenza | 0 |
| Non-cash royalty revenue | 7,932 |
| Non-cash interest expense | 8,259 |
| Non-cash lease expense | 1,784 |
| Other non-cash items | 0 |
| (gain) loss on disposal of assets | 10 |
| Accounts receivable | 9,063 |
| Inventory | 7,910 |
| Prepaid expenses and other current assets | -2,769 |
| Other non current assets | 0 |
| Accounts payable | -280 |
| Accrued expenses and other current liabilities | -6,834 |
| Lease liabilities | -699 |
| Deferred revenue | -5,398 |
| Other non current liabilities | -916 |
| Net cash used in operating activities | -81,040 |
| Purchases of marketable securities | 208,336 |
| Proceeds from sales and maturities of marketable securities | 96,142 |
| Purchases of property, equipment and software | 1,914 |
| Proceeds from sale of margenza | 0 |
| Proceeds from sales of equipment | 11 |
| Net cash provided by (used in) investing activities | -114,097 |
| Proceeds from issuance of common stock, net of offering costs | 0 |
| Proceeds from stock option exercises and espp purchases | 129 |
| Taxes paid related to net share settlement of equity awards | 288 |
| Principal payments on royalty monetization arrangement | 0 |
| Net proceeds from sale of future royalties | 69,673 |
| Net cash provided by financing activities | 69,514 |
| Net change in cash and cash equivalents | -125,623 |
| Cash and cash equivalents at beginning of period | 182,840 |
| Cash and cash equivalents at end of period | 57,217 |
MACROGENICS INC (MGNX)
MACROGENICS INC (MGNX)